Evidence map›Paper›PMID 37639180›Full record

SynthesisDrugs2023

Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Huilei Zhao, Yang Liu, Menglu Liu, Yi Xu, Qin Ling, Weichun Lin, Jing Zhang, Zhiwei Yan, Jianyong Ma, Weiguang Li and 4 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Obesity and Heart Failure: Introducing the Theme.Journal of cardiovascular development and disease · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Huilei Zhao *Department of Anesthesiology, The Third Hospital of Nanchang, Nanchang, Jiangxi, China.
Yang Liu *Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Menglu LiuDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
Yi XuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Qin LingDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Weichun LinDepartment of Gastroenterology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jing ZhangDepartment of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Zhiwei YanDepartment of Sports Rehabilitation, Shenyang Sport University, Shenyang, Liaoning, China.
Jianyong MaDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Weiguang LiDepartment of Rehabilitation, Liaoning Province Jinqiu Hospital, Shenyang, Liaoning, China.
Yujie ZhaoDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
Peng YuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. yupeng_jxndefy@163.com.
Xiao LiuDepartment of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. liux587@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-5570-289X
Jingfeng WangDepartment of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Nanchang University · CNSun Yat-sen University · CNZhengzhou People's Hospital · CNFujian Normal University · CNThird Hospital of Nanchang · CN

Funding

China Postdoctoral Science Foundation Nos. 2021M703724National High Technology Research and Development Program of Guangzhou Nos. 20180304001National High Technology Research and Development Program of Guangzhou Nos. 2019GZR110406004National Natural Science Foundation of China Nos. 21866019National Natural Science Foundation of China Nos. 82100869National Natural Science Foundation of China Nos. 82160371Natural Science Foundation of Guangdong Province Nos. 202201011395Natural Science Foundation of Guangdong Province Nos. 2022A1515010582Natural Science Foundation of Jiangxi Province 202002BAB216022Natural Science Foundation of Jiangxi Province 202004BCJL23049Natural Science Foundation of Jiangxi Province 20212BAB216051Natural Science Foundation of Jiangxi Province Nos. 20192ACBL21037Science and Technology Projects in Guangzhou Nos. 202102010007the National Natural Science Foundation of China Nos. 82100347
6 · The paper itself

Abstract

backgroundGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, there remains uncertainty about the efficiency of GLP-1 RAs in patients with heart failure (HF).

methodsRandomized placebo-controlled trials (RCTs) that reported the effect of GLP-1 RAs on prognosis in patients with HF were identified by searching databases. The primary outcome was defined as MACE. Trail Sequential Analysis (TSA) was used to evaluate the reality and authenticity.

resultsNine RCTs involving 8920 patients with HF were included. GLP-1 RAs significantly reduced the risk of MACE compared with placebo (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.77-0.98) in HF coexisting with T2DM. The benefit was not observed in all-cause death (HR 0.99, 95% CI 0.84-1.15), hospitalization for heart failure (HR 1.04, 95% CI 0.89-1.22), cardiovascular death (HR 0.95, 95% CI 0.79-1.16), myocardial infarction (HR 0.88, 95% CI 0.71-1.08), stroke (HR 1.03, 95% CI 0.75-1.43) and death or hospitalization for HF (HR 1.07, 95% CI 0.78-1.46). GLP-1 RAs did not improve the change in LVEF (mean difference [MD]): - 0.86, p = 0.12, left-ventricular end-diastolic volume (LVEDV) (MD: 3.54, p = 0.11), left-ventricular end-systolic volume (LVESV) (MD: 2.78, p = 0.07) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) (MD: - 140.36, p = 0.08). However, GLP-1 RAs significantly increased the change in the 6-min walk test (MWT) distance (MD: 19.74, p = 0.002). In the subgroup analyses, human GLP-1 RAs, but not nonhuman GLP-1 RAs, reduced the risk of MACE in patients with HF (p interaction = 0.11). Grading of Recommendations Assessment, Development and Evaluation (GRADE) showed moderate certainty for MACE, all-cause death and hospitalization for HF. Trail Sequential Analysis revealed that there may be a high possibility of false positive results for MACE.

conclusionCompared with placebo, GLP-1 RAs may reduce the risk of MACE in patients with HF coexisting with T2DM, with a more significant efficiency of human GLP-1 RAs. More RCTs are needed to assess the cardiovascular benefits of GLP-1 RAs in HF, regardless of T2DM. REGISTRATION: The protocol for this meta-analysis is registered on PROSPERO [CRD42022357886].

Indexed as

Diabetes Mellitus, Type 2Heart FailureGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansRandomized Controlled Trials as TopicGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor

Identifiers

PMID37639180
OpenAlexW4386209904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.